In-licensing and Other Research and Development Agreements	9 Months Ended
Sep. 30, 2026
In-Licensing And Other Research And Development Agreements [Abstract]
In-licensing and Other Research and Development Agreements	In-licensing and Other Research and Development Agreements Stanford License Agreement In April 2016, Eidos entered into a license agreement with the Board of Trustees of the Leland Stanford Junior University (“Stanford University”), relating to Eidos’ drug discovery and development initiatives. Under this agreement and its amendments, Eidos has been granted certain worldwide exclusive licenses to make, use, and sell products that are covered by licensed patent rights. Eidos may also be required to make future payments of up to approximately $1.0 million to Stanford University upon achievement of specific intellectual property, clinical and regulatory milestone events, and pay royalties of up to low single-digit percentages on future net sales, if any. In addition, Eidos is obligated to pay Stanford University a percentage of nonroyalty revenue received by Eidos from its sublicensees, with the amount owed decreasing annually for three years based on when the applicable sublicense agreement is executed. Additionally, under the license agreement with Stanford University, we will pay Stanford University a portion of all nonroyalty sublicensing consideration attributable to the sublicense of the licensed compounds. During the three and nine months ended September 30, 2026, we incurred $8.4 million and $17.0 million, respectively, in royalties related to commercial sales of Attruby and Beyonttra. During the three and nine months ended September 30, 2025, we incurred $1.9 million and $3.6 million, respectively, in royalties related to commercial sales of Attruby and Beyonttra. For the three and nine months ended September 30, 2026, we incurred a $4.5 million license fee payable to Stanford University, which was related to the $75.0 million sales milestone achieved in September 2026 under the Bayer License Agreement (refer to Note 10), which was recognized within “Cost of license, services, and royalty revenue” on our condensed consolidated statements of operations. For the three and nine months ended September 30, 2025, we incurred nil and $6.9 million, respectively, of license fees payable to Stanford University, which was related to the regulatory milestone achieved in February 2025 under the Bayer License Agreement as well as the regulatory milestone achieved in May 2025 under the Eidos-Alexion License Agreement (refer to Note 10), and were capitalized as finite-lived intangible assets. Other License and Collaboration Agreements In addition to the agreements described above, we have also entered into other license and collaboration agreements with various institutions and business entities on terms similar to those described above, none of which are material individually or in the aggregate.

In April 2016, Eidos entered into a license agreement with the Board of Trustees of the Leland Stanford Junior University (“Stanford University”), relating to Eidos’ drug discovery and development initiatives. Under this agreement and its amendments, Eidos has been granted certain worldwide exclusive licenses to make, use, and sell products that are covered by licensed patent rights. Eidos may also be required to make future payments of up to approximately $1.0 million to Stanford University upon achievement of specific intellectual property, clinical and regulatory milestone events, and pay royalties of up to low single-digit percentages on future net sales, if any. In addition, Eidos is obligated to pay Stanford University a percentage of nonroyalty revenue received by Eidos from its sublicensees, with the amount owed decreasing annually for three years based on when the applicable sublicense agreement is executed.

Additionally, under the license agreement with Stanford University, we will pay Stanford University a portion of all nonroyalty sublicensing consideration attributable to the sublicense of the licensed compounds. During the three and nine months ended September 30, 2026, we incurred $8.4 million and $17.0 million, respectively, in royalties related to commercial sales of Attruby and Beyonttra. During the three and nine months ended September 30, 2025, we incurred $1.9 million and $3.6 million, respectively, in royalties related to commercial sales of Attruby and Beyonttra. For the three and nine months ended September 30, 2026, we incurred a $4.5 million license fee payable to Stanford University, which was related to the $75.0 million sales milestone achieved in September 2026 under the Bayer License Agreement (refer to Note 10), which was recognized within “Cost of license, services, and royalty revenue” on our condensed consolidated statements of operations. For the three and nine months ended September 30, 2025, we incurred nil and $6.9 million, respectively, of license fees payable to Stanford University, which was related to the regulatory milestone achieved in February 2025 under the Bayer License Agreement as well as the regulatory milestone achieved in May 2025 under the Eidos-Alexion License Agreement (refer to Note 10), and were capitalized as finite-lived intangible assets.